WASHINGTON, Feb. 28 (TNSFR) -- The Rapid Response Partnership Vehicle (RRPV) has announced an expansion of its membership, adding several biotechnology, pharmaceutical, and medical research companies from the United States and abroad.

In a notification filed on January 16, 2025, with the Attorney General and the Federal Trade Commission, RRPV disclosed the addition of multiple organizations engaged in vaccine development, diagnostics, and biopharmaceutical manufacturing.